Skip to content

Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patients

Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on uncontrolled type 2 Diabetic Patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200810048355N1
Enrollment
128
Registered
2021-06-13
Start date
2021-06-22
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Melitus Type tow. Diabetes mellitus type 2 (formerly noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterised by high blood glucose in the context of insulin resistance and relative insulin deficiency.

Interventions

Intervention 1: Intervention group: The first group receives 100 mg of Cytagliptin daily at the same time as the previous dose of metformin for 3 months. Intervention 2: Intervention group: The second

Sponsors

Vice Chancellor for Research, Islamic Aazad University, Najafabad branch
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes Age between 18 and 80 (HbA1c between 6.5-9) during the last 6 months Metformin ± Sulfonylurea (often gliclazide) ± Pioglitazone

Exclusion criteria

Exclusion criteria: GFR<45 Hepatic Failure Ill and toxic patients DM Type 1 Dissatisfaction with continued cooperation Insulin Use GLP-1 agonists

Design outcomes

Primary

MeasureTime frame
FBS. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Blood sample.;HbA1C. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Blood sample.;Blood pressure. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Mercury barometer.;Lipid profile. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Blood sample.;Body mass index. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Height and Weight measurment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParichehr Vahabi Anaraki MD

Islamic Azad University

pari.vahabi@med.mui.ac.ir+98 31 4229 2929

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026